MedTrace Logo

The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients

NCT04028544 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5380

Last updated 2019-07-22

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study including patients with ejection fraction decreased heart failure under standardized treatment, to evaluate QiShenYiQi (QSYQ) dropping pill's curative effect in reducing cardiovascular death and heart failure rehospitalization compared with placebo.

Conditions

Interventions

DRUG

Qishenyiqi dropping pills

on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day

DRUG

Placebo

on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day

Sponsors & Collaborators

  • Tianjin Tasly Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    lead OTHER

Principal Investigators

  • Jian Zhang, MD · Heart Failure Center, Fuwai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2020-09-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04028544 on ClinicalTrials.gov